Presentations to highlight clinical utility of ZYNLONTA® (loncastuximab tesirine-lpyl) as a single agent and in combination Oral presentation to include.
The stock of Adc Therapeutics SA (NYSE: ADCT) has increased by 3.40 when compared to last closing price of 0.81.Despite this, the company has seen a loss of -2.62% in its stock price over the last five trading days. GlobeNewsWire reported 2023-09-05 that LAUSANNE, Switzerland, Sept. 05, 2023 (GLOBE
Adc Therapeutics SA (NYSE: ADCT)’s stock price has gone rise by 12.31 in comparison to its previous close of 0.72, however, the company has experienced a 4.26% increase in its stock price over the last five trading days. GlobeNewsWire reported 2023-09-05 that LAUSANNE, Switzerland, Sept. 05, 2